What are you looking for?

Detection of Mycoplasma in Biopharmaceuticals, Vaccines, and Gene Cell Therapies

September 03, 2019
Download Now

The detection of mycoplasma contamination is of utmost concern in bio-therapeutic and vaccine manufacturing. Now that streamlined assay validation procedures and GMP-validated NAT tests are readily available, these methods can provide manufacturers with confidence in results required in production and batch release of products. The high reproducibility and fast throughput of cutting-edge NAT-based methods reduces the amount of time needed for development, safety testing, and final marketing of novel biotechnology products.


Please complete the form to download your copy.

    Related White Papers

    News & Insights

    • SGS Headquarters

    1 Place des Alpes,

    P.O. Box 2152 1211,

    Geneva Switzerland